Crossmark

Effect of a moderate CYP3A inducer efavirenz on the pharmacokinetics of fuzuloparib: An open-label, fixed sequence study in Chinese healthy male subjects

Crossref DOI link: https://doi.org/10.1007/s10637-023-01331-0

Published Online: 2023-02-17

Published Print: 2023-04

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Hu, Linlin

Dou, Ting

Sun, Qiuyue

Tang, Lu

Cai, Mingmin

Qian, Wei

Wang, Huiping
License Information

Text and Data Mining valid from 2023-02-17

Version of Record valid from 2023-02-17
More Information

Article History

Received: 15 December 2022

Accepted: 10 January 2023

First Online: 17 February 2023

Declarations

:

: Informed consent was obtained from all individual participants included in the study.

: This study was performed in line with the principles of the Declaration of Helsinki. The study protocol was approved (approval number, 2021ZDSYLL079-P01) by the Ethics Committee of the Zhongda Hospital, Medical School, Southeast University (Nanjing, China).

: The authors declare no conflicts of interest.

Document is current

Any future updates will be listed below